Factor VIII products and inhibitor development: The SIPPET study (survey of inhibitors in plasma-product exposed toddlers)

Haemophilia

Volumn 13, Issue SUPPL. 5, 2007, Pages 65-68

  Mannucci, P M ^a   Gringeri, A ^a   Peyvandi, F ^a   Santagostino, E ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; CALCULATION; CLINICAL TRIAL; DRUG SAFETY; HEMOPHILIA A; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INCIDENCE; PRIORITY JOURNAL; RANDOMIZATION; RISK FACTOR; SAMPLE SIZE;

EID: 37149022850     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2007.01580.x     Document Type: Article

References (15)

1. Gringeri A, Mantovani LG, Scalone L, Mannucci PM. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102: 2358-2363.
2. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-435.
3. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: The importance of patient age. Br J Haematol 2001; 113: 600-603.
4. Addiego J, Kasper C, Abildgaard C et.al. Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993; 342: 462-464.
5. Schimpf K, Schwarz P, Kunschak M. Zero incidence of inhibitors in previously untreated patients who received intermediate purity factor VIII concentrate or factor IX complex. Thromb Haemost 1995; 73: 553-555.
6. Guerois C, Laurian Y, Rothschild C et.al. Incidence of factor VIII inhibitor development in severe hemophilia A patients treated only with one brand of highly purified plasma-derived concentrate. Thromb Haemost 1995; 73: 215-218.
7. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 1993; 328: 453-459.
8. Rothschild C, Laurian Y, Satre EP et.al. French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost 1998; 80: 779-783.
9. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001; 38: 52-59.
10. Kreuz W, Gill JC, Rothschild C et.al. Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: Results of an international clinical investigation. Thromb Haemost 2005; 93: 457-467.
11. Goudemand J, Rothschild C, Demiguel V et.al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
12. Gouw SC, Van der Bom JG, Van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: The CANAL cohort study. Blood 2007; 109: 4648-4654.
13. Suzuki T, Arai M, Amano K, Kagawa K, Fukutake K. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor. Thromb Haemost 1996; 76: 749-754.
14. Berntorp E, Ekman M, Gunnarsson M, Nilsson IM. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations. Haemophilia 1996; 2: 95-99.
15. Dasgupta S, Repesse Y, Bayry J et.al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-612.